Basilea Financial Statements From 2010 to 2025
| BPMUF Stock | USD 52.83 0.00 0.00% |
Check Basilea Pharmaceutica financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Basilea Pharmaceutica's main balance sheet or income statement drivers, such as , as well as many indicators such as . Basilea financial statements analysis is a perfect complement when working with Basilea Pharmaceutica Valuation or Volatility modules.
Basilea |
Basilea Pharmaceutica AG Company Current Valuation Analysis
Basilea Pharmaceutica's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Basilea Pharmaceutica Current Valuation | 724.26 M |
Most of Basilea Pharmaceutica's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Basilea Pharmaceutica AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Basilea Pharmaceutica AG has a Current Valuation of 724.26 M. This is 94.96% lower than that of the Healthcare sector and 84.41% lower than that of the Biotechnology industry. The current valuation for all United States stocks is 95.64% higher than that of the company.
Basilea Pharmaceutica Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Basilea Pharmaceutica's current stock value. Our valuation model uses many indicators to compare Basilea Pharmaceutica value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Basilea Pharmaceutica competition to find correlations between indicators driving Basilea Pharmaceutica's intrinsic value. More Info.Basilea Pharmaceutica AG is number one stock in return on asset category among its peers. It also is number one stock in profit margin category among its peers fabricating about 0.21 of Profit Margin per Return On Asset. The ratio of Return On Asset to Profit Margin for Basilea Pharmaceutica AG is roughly 4.66 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Basilea Pharmaceutica's earnings, one of the primary drivers of an investment's value.About Basilea Pharmaceutica Financial Statements
Basilea Pharmaceutica stakeholders use historical fundamental indicators, such as Basilea Pharmaceutica's revenue or net income, to determine how well the company is positioned to perform in the future. Although Basilea Pharmaceutica investors may analyze each financial statement separately, they are all interrelated. For example, changes in Basilea Pharmaceutica's assets and liabilities are reflected in the revenues and expenses on Basilea Pharmaceutica's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Basilea Pharmaceutica AG. Please read more on our technical analysis and fundamental analysis pages.
Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Basel, Switzerland. BASILEA PHARMACEUTICA is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
| EBR | Centrais Electricas Brasileiras | |
| HE | Hawaiian Electric Industries | |
| VFC | VF Corporation | |
| BVHMF | Vistry Group PLC | |
| S | SentinelOne |
Other Information on Investing in Basilea Pink Sheet
Basilea Pharmaceutica financial ratios help investors to determine whether Basilea Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Basilea with respect to the benefits of owning Basilea Pharmaceutica security.